Renal Cancer Drugs Market
Global Renal Cancer Drugs Market Size, Share & Trends Analysis Report By Cancer Type (Renal Cancer Carcinoma, Clear Cell Renal Cell Carcinoma, Non-Clear Renal Cell Carcinoma, and Others), By Drug Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, and Cytokine Immunotherapy (IL-2)), By Therapeutic Class (Targeted Therapy and Immunotherapy, and Chemotherapy), and Forecast 2019-2025 Update Available - Forecast 2024-2030
The global renal cancer drug market is projected to grow at a significant CAGR during the forecast period. Renal cancer occurs in the lining of the proximal convoluted tubule of the kidney. Several factors leading to renal cancer include obesity, smoking, high blood pressure, Von Hippel-Lindau (VHL) syndrome, and long-term dialysis, among others. Whereas, symptoms include blood in the urine, mass or lump in the abdomen, weight loss, and lethargy among others. The primary factors that drive the growth of the market include increased incidences of renal cancer, rising older population, and the advent of advanced diagnostic techniques and drugs for the detection and treatment. However, increased preferences of peoples towards the generic drugs owing to the higher prices of the branded drug are the primary factor hindering the growth of the market.
Besides, key players' contributions along with the ongoing clinical trials of several drugs are likely to create scope for the market growth. For instance, in January 2020, Aravive, Inc., a clinical-stage biopharmaceutical company, announced that the US FDA has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead candidate, AVB-500, for the treatment of clear cell renal cell carcinoma (ccRCC). Such clinical trials for the development of novel drugs are estimated to flourish the market growth during the forecast period.
Segmental Outlook
The global renal cancer drug market is segmented on the basis of cancer type, drug class, and therapeutic class. Based on the cancer type, the market is segmented into renal cancer carcinoma, clear cell renal cell carcinoma, non-clear renal cell carcinoma, and others. Based on the drug class, the market is segmented into angiogenesis inhibitors, monoclonal antibodies, mTOR inhibitors, and cytokine immunotherapy (IL-2. Based on the therapeutic class, the market is segmented into targeted therapy, immunotherapy, and chemotherapy.
Renal Cancer Carcinoma Holds the Significant Market Share
Amongst the cancer type of the market, renal cancer carcinoma is estimated to hold a significant share in the market. The segmental growth is attributed to the increased prevalence of renal cancer carcinoma amongst the peoples along with several clinical trials going on for the development of the drug for the diseases. As per the American Society of Clinical Oncology (ASCO), renal cell carcinoma is the common type of adult kidney cancer, that accounts for approximately 85% of diagnoses. It occurs in the proximal renal tubules that make up the kidney’s filtration system. There are numerous of these tiny filtration units in each kidney.
Regional Outlook
The global renal cancer drugs market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is estimated to exhibit significant growth in the global market during the forecast period. The regional growth is attributed to the presence of a large pool of geriatric population in economies such as Japan. Further, China also contributes significantly to the market growth owing to the several government norms such as Healthy China 2020. Additionally, initiatives by the Chinese government such as 12th Five-Year Plan measures targeting biotechnology as a vital development sector along with the footprints of a large consumer base with strong unmet clinical needs are also likely to flourish the regional growth of the market. Furthermore, North America is expected to hold a considerable share in the market during the forecast period.
Global Renal Cancer Drugs Market by Region, 2018 (%)
Market Players Outlook
Some of the prominent players operating in the global renal cancer drugs market include Pfizer, Inc., Bayer AG, Bristol Myers Squibb Co., Amgen Inc., GlaxoSmithKline Plc, Prometheus Laboratories Inc., Rosetta Genomics Ltd., Sysmex Corp., and others. These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global renal cancer drugs market.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Bayer AG
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Pfizer Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Novartis International AG
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Bristol-Myers Squibb Co.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Renal Cancer Drugs Market by Cancer Type
5.1.1. Renal Cancer Carcinoma
5.1.2. Clear Cell Renal Cell Carcinoma
5.1.3. Non-Clear Renal Cell Carcinoma
5.1.4. Others
5.2. Global Renal Cancer Drugs Market by Drug Class
5.2.1. Angiogenesis Inhibitors
5.2.2. Monoclonal Antibodies
5.2.3. mTOR Inhibitors
5.2.4. Cytokine Immunotherapy (IL-2)
5.3. Global Renal Cancer Drugs Market by Therapeutic Class
5.3.1. Targeted Therapy
5.3.2. Immunotherapy
5.3.3. Chemotherapy
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Active Biotech AB
7.2. Amgen Inc.
7.3. Aravive, Inc.
7.4. Argos Therapeutics Inc.
7.5. Bayer AG
7.6. Bristol Myers Squibb Co.
7.7. Cipla Ltd.
7.8. Eisai Co., Ltd.
7.9. Exelixis, Inc.
7.10. Genentech, Inc.
7.11. GlaxoSmithKline Plc
7.12. Myriad Genetics Inc.
7.13. NanoString Technologies Inc.
7.14. NeoGenomics Laboratories Inc.
7.15. Novartis International AG
7.16. Pfizer, Inc
7.17. Prometheus Laboratories Inc.
7.18. Rosetta Genomics Ltd.
7.19. Sysmex Corp.
1. GLOBAL RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
2. GLOBAL RENAL CANCER CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL CLEAR CELL RENAL CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL NON-CLEAR RENAL CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL OTHER RENAL CANCER TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
7. GLOBAL ANGIOGENESIS INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL MTOR INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2018-2025 ($ MILLION)
12. GLOBAL TARGETED THERAPY FOR RENAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL IMMUNOTHERAPY FOR RENAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
14. GLOBAL CHEMOTHERAPY FOR RENAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
15. GLOBAL RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
16. NORTH AMERICAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
17. NORTH AMERICAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
18. NORTH AMERICAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
19. NORTH AMERICAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2018-2025 ($ MILLION)
20. EUROPEAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
21. EUROPEAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
22. EUROPEAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
23. EUROPEAN RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2018-2025 ($ MILLION)
24. ASIA-PACIFIC RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
25. ASIA-PACIFIC RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
26. ASIA-PACIFIC RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
27. ASIA-PACIFIC RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2018-2025 ($ MILLION)
28. REST OF THE WORLD RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
29. REST OF THE WORLD RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
30. REST OF THE WORLD RENAL CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2018-2025 ($ MILLION)
1. GLOBAL RENAL CANCER DRUGS MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
2. GLOBAL RENAL CANCER DRUGS MARKET SHARE BY DRUG CLASS, 2018 VS 2025 (%)
3. GLOBAL RENAL CANCER DRUGS MARKET SHARE BY THERAPEUTIC CLASS, 2018 VS 2025 (%)
4. GLOBAL RENAL CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
5. US RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
7. UK RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
8. FRANCE RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
9. GERMANY RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
10. ITALY RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
11. SPAIN RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
12. ROE RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
13. INDIA RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
14. CHINA RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
15. JAPAN RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF ASIA-PACIFIC RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
17. REST OF THE WORLD RENAL CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
